ArticleFrontiers in oncology2019
IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways.
Xiaomeng Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
14 papers cite it
this papercites it
ArticleFrontiers in oncology2019
Xiaomeng Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.